BIO International 2025: The new CEO of Sweden's Hansa Biopharma discusses potential uses of the company's IgG busting drug, imlifidase, including for kidney transplant and along with gene therapy

Renée Aguiar-Lucander describes the kidney transplant population that the therapy currently has conditional approval with the EMA for, and how Hansa it trying to expand on it. Plus, development work in Guillain-Barré syndrome and gene therapy.